Navigating the Menopausal Transition: A Clinical Whitepaper on Symptom Management and Evidence-Based Therapeutic Strategies

Executive Summary

The medical understanding of menopause has undergone a profound evolution, moving from a simplified model of estrogen deficiency defined by vasomotor symptoms (VMS) to a complex endocrine transition with systemic, multi-system implications. This whitepaper synthesizes the current, evidence-based consensus from leading medical societies—including The Menopause Society (formerly NAMS), the American College of Obstetricians and Gynecologists (ACOG), the Society of Obstetricians and Gynaecologists of Canada (SOGC), and the International Menopause Society (IMS)—to provide a clinical framework for navigating this transition.

This report details several critical paradigm shifts in menopause management. First, it presents an expanded model of symptomatology that looks beyond VMS to include the chronic, progressive nature of Genitourinary Syndrome of Menopause (GSM) [1] and the newly conceptualized Musculoskeletal Syndrome of Menopause (MSM).[2] Second, it analyzes the definitive reappraisal of Menopausal Hormone Therapy (MHT), which, based on nuanced re-analysis of the Women's Health Initiative (WHI) data, is re-established as the safest and most effective first-line therapy for most symptomatic women initiating use within the "window of opportunity".[4] Third, it details the emergence of novel, targeted non-hormonal therapeutics, specifically the 2023 FDA approval of neurokinin 3 receptor (NK3R) antagonists, which represent an entirely new class of VMS treatment.[6]

Finally, this whitepaper contextualizes the current 2024-2025 academic discourse between the "empowerment" model, which cautions against overmedicalization (as highlighted in *The Lancet* 2024 Series) [7], and the clinical rebuttal from the IMS (in its 2024 White Paper), which reaffirms the critical role of evidence-based medical therapy for symptomatic women.[8] The

objective of this report is to equip individuals with the complete, evidence-based data from primary medical society guidelines [10] to facilitate high-level, shared decision-making with their clinician.

Part 1: The Menopausal Transition: A Clinical and Biological Framework

A precise clinical nomenclature is essential for diagnosis and management. The stages of reproductive aging are defined by clinical consensus guidelines from major medical societies.[10]

1.1 Defining the Stages: Clinical Consensus

The menopausal transition is a multi-year process, not a singular event. The stages are defined clinically, primarily by menstrual cycle characteristics.[14]

- **Pre-menopause:** The time before any menopausal symptoms or menstrual irregularities begin.[14]
- **Perimenopause (Menopausal Transition):** This is the transitional phase leading up to the final menstrual period. It is marked by hormonal fluctuation and the onset of symptoms, most notably irregular periods.[14] It often begins in a woman's 40s, but the timing is highly variable.[15] Perimenopause is clinically identified by specific changes in the menstrual cycle:
  - **Early Perimenopause:** Characterized by a persistent difference in the length of the menstrual cycle of seven days or more.[15]
  - **Late Perimenopause:** Defined by having 60 days or more between periods, indicating a more significant decline in ovarian function.[15]
- **Menopause:** This is a *retrospective* diagnosis. Menopause is defined as the point in time 12 consecutive months after the final menstrual period.[11] The average age of natural menopause in Western societies is 51 years.[14]
- **Postmenopause:** This term describes the entire span of time after menopause is diagnosed.[14]
- **Induced and Premature Menopause:** It is critical to distinguish natural menopause from *induced* menopause (caused surgically by bilateral oophorectomy or medically by chemotherapy or pelvic radiation) or *premature/early menopause*.[14] Premature Ovarian

Insufficiency (POI) is spontaneous menopause before age 40, while early menopause occurs before age 45.[14] These women face higher lifetime risks of bone loss, heart disease, and cognitive disorders due to prolonged estrogen deficiency. Medical guidelines recommend that these women use MHT until at least the mean age of menopause, unless contraindicated.[20]

1.2 The Hormonal Pathophysiology: An Endocrine Cascade

The symptoms of perimenopause and menopause are driven by profound changes in the reproductive endocrine system.

1. **Ovarian Follicular Exhaustion:** The transition begins as the number and quality of ovarian follicles decline, leading to a loss of ovarian follicular activity.[19]
2. **Hormonal Fluctuation and Decline:** As ovarian function wanes, the production of key hormones changes. In perimenopause, estrogen (specifically estradiol) and inhibin B levels begin to fluctuate erratically and ultimately fall.[15] Progesterone production also decreases due to a higher frequency of anovulatory cycles (cycles where no egg is released).[16]
3. **The FSH Feedback Loop:** The pituitary gland, which regulates the ovaries, senses the low levels of estrogen and inhibin B (which normally provide negative feedback). In response, it increases its output of Follicle-Stimulating Hormone (FSH) in an attempt to stimulate the ovaries.[22] A persistently elevated FSH level is a classic (though not always required) biomarker of the menopausal state.[22]

For most women, hormonal testing (e.g., FSH levels) is *not* recommended to diagnose the menopausal transition.[24] The diagnosis is clinical, based on the menstrual cycle criteria outlined above.[23] However, the Endocrine Society suggests that in women who have undergone a hysterectomy (and thus have no menstrual cycle to track), a presumptive diagnosis of menopause can be made based on the presence of VMS combined with replicate laboratory measures of FSH and serum estradiol.[23]

1.3 The "Transition" vs. The "Event"

The clinical definitions consistently differentiate "perimenopause" (a transition) from "menopause" (a retrospective event). This distinction is not merely academic; it has profound clinical implications.[14] The primary medical challenge for most women is not the static,

low-estrogen state of postmenopause, but the *process* of the perimenopausal transition itself.

During this multi-year phase, it is the *fluctuation* and unpredictability of estrogen levels—the rising and falling—that can be highly destabilizing.[15] This hormonal volatility explains why many women experience the most severe vasomotor symptoms, mood disturbances, and sleep disruption *before* their final menstrual period.[26] This reframes the patient experience from passively "waiting for it to be over" to actively managing a multi-year, dynamic endocrine process that requires medical consultation and strategy.

Part 2: The Full Spectrum of Perimenopausal and Menopausal Symptomatology

The classic portrayal of menopause as a syndrome of "hot flashes" is clinically incomplete. Research has validated a complex, multi-system constellation of symptoms. Up to 80% of women experience symptoms, with 20-25% reporting them as severe enough to disrupt daily life.[14]

2.1 Cardinal Symptoms: Vasomotor Symptoms (VMS)

VMS are the "cardinal" or "hallmark" symptoms of the menopausal transition and the most common reason women seek medical care.[14]

- **Clinical Presentation:** Defined as hot flashes (also called flushes) and night sweats. These are characterized by episodes of profuse heat, flushing, and sweating, particularly around the upper body.[28]
- **Prevalence and Duration:** VMS affect up to 80-82% of women.[14] Longitudinal cohort studies, such as the Study of Women's Health Across the Nation (SWAN), have been critical in defining their natural history. The median duration of VMS is 7.4 years, and for some women, symptoms may persist for more than a decade.[27]
- **Pathophysiology (The KNDy Neuron Hypothesis):** A significant advance in medical understanding is the clarification of the VMS mechanism. VMS are *not* a direct result of low estrogen, but a *neuroendocrine* disruption. They originate in the hypothalamus, the brain's thermoregulatory center. Declining estrogen levels are thought to cause hypertrophy and hyperactivity of a specific group of neurons known as Kisspeptin/Neurokinin B/Dynorphin (KNDy) neurons. This hyperactivity narrows the

thermoneutral zone, making the body highly sensitive to small changes in core temperature and triggering a hot flash (a powerful heat-dissipation response).[29]

- **Impact:** VMS significantly disrupt quality of life, interfere with sleep, and can reduce work productivity.[29]

2.2 Genitourinary Syndrome of Menopause (GSM): A Chronic and Progressive Condition

In 2014, the International Society for the Study of Women's Sexual Health and NAMS adopted the term "Genitourinary Syndrome of Menopause" (GSM) to replace the older, less accurate term "Vulvovaginal Atrophy" (VVA).[1] This shift was critical because GSM is a more accurate, inclusive, and non-stigmatizing term that correctly links a broad cluster of symptoms to the hypoestrogenic state of menopause.[35]

- **Clinical Triad of Symptoms:** GSM is a cluster of signs and symptoms affecting the vulva, vagina, and lower urinary tract.[1] It is composed of three symptom categories:
  1. **Genital Symptoms:** Vaginal dryness, burning, and irritation.[1]
  2. **Sexual Symptoms:** Lack of lubrication, dyspareunia (painful intercourse), and impaired sexual function.[1]
  3. **Urinary Symptoms:** Urinary urgency, dysuria (painful urination), and recurrent urinary tract infections (UTIs).[1]
- **Pathophysiology:** GSM is caused by the profound decrease in estrogen and other sex steroids (like androgens) in the urogenital tissues, which are rich in hormone receptors.[36] This hormonal loss leads to a cascade of physical changes: the vaginal epithelium thins and becomes pale, less elastic, and fragile; vaginal rugae (folds) are lost; vaginal pH rises to above 4.5; and the vaginal microbiome shifts, resulting in a loss of protective *Lactobacilli*.[35]
- **Prevalence and Diagnosis:** GSM affects a large percentage of postmenopausal women, with prevalence estimates ranging from 27% to 84%.[36] Diagnosis is made clinically based on a focused patient history and a genitourinary examination.[41] The 2025 AUA/SUFU guidelines emphasize that documentation of hormone levels is *not* necessary for diagnosis.[41]

2.3 Neuropsychiatric and Cognitive Manifestations

The hormonal flux of perimenopause has a direct impact on brain function, affecting both mood and cognition.

- **Psychological Sequelae:** The menopausal transition is associated with a well-documented increased risk of mood disturbances, including mood swings, irritability, anxiety, and new-onset or recurrent depressive symptoms.[15] Longitudinal data from the SWAN study confirms that the risk for high depressive symptoms is significantly greater *during* the transition, particularly in the later stages, which is linked to hormonal fluctuations.[27] This risk is notably higher in women with a prior history of depression or premenstrual dysphoric disorder (PMDD).[44] The clinical presentation of perimenopausal depression may also differ from non-menopausal episodes, often featuring more agitation, irritability, pronounced sleep disturbance, and memory problems, with potentially less anhedonia or cognitive distortions of guilt.[47]
- **Cognitive Changes ("Brain Fog"):** A "foggy brain" or "brain fade" is a major complaint among perimenopausal women.[48] This subjective experience is validated by research linking cognitive changes to estrogen decline, as estrogen receptors are widespread in the brain and influence verbal memory.[48] Objective cognitive changes identified in research include reduced processing speed and diminished verbal memory (the ability to encode and retrieve words).[48] These cognitive symptoms are distinct but are significantly exacerbated by co-morbidities, aging, and, most acutely, by VMS-induced insomnia.[48]

2.4 The Musculoskeletal Syndrome of Menopause (MSM)

A newer, unifying concept in menopause medicine is the "musculoskeletal syndrome of menopause" (MSM), proposed in a 2024 review in the journal *Climacteric*.[2] This term seeks to unify a constellation of musculoskeletal symptoms that are highly prevalent but often treated in isolation or misattributed solely to aging.

- **Prevalence:** Over 70% of women will experience musculoskeletal symptoms during the menopausal transition, and for 25%, these symptoms may be disabling.[2]
- **Pathophysiology:** Estrogen deficiency has direct, detrimental effects on nearly all musculoskeletal tissues, including bone, tendon, muscle, and cartilage.[50] The fall in estradiol is linked to five primary pathological changes: (1) an increase in systemic inflammation, (2) a decrease in bone mineral density (BMD), (3) progression of arthritis and cartilage degeneration, (4) sarcopenia (loss of muscle mass and strength), and (5) a decrease in the proliferation of muscle stem cells (satellite cells) needed for repair.[50]
- **Clinical Manifestations:**
    - **Arthralgia:** Widespread joint pain, swelling, and stiffness are common complaints.[2]
    - **Sarcopenia:** The menopausal transition accelerates the loss of muscle mass,

particularly type II (fast-twitch) muscle fibers, and strength. Women lose approximately 0.6% of their muscle mass per year after menopause.[50]
    - **Osteoarthritis (OA) Progression:** Estrogen deficiency is an identified risk factor for cartilage degeneration, which can initiate or accelerate the progression of OA.[53]
- **Clinical Significance:** The MSM concept is crucial for clinicians (especially primary care physicians, gynecologists, and orthopedists) to avoid dismissing these complaints as inevitable "signs of aging." Recognizing the underlying endocrine cause (estrogen loss) allows for proper risk assessment and prophylactic management, reassuring patients that these changes are physiological and treatable.[52]

2.5 The Interconnected Symptom Cascade

The full spectrum of menopausal symptoms cannot be viewed as a simple checklist; it is an interconnected cascade. The medical literature reveals a complex web of causal links. Vasomotor symptoms (VMS), particularly night sweats, are a primary driver of sleep disturbances and insomnia.[14] This VMS-induced insomnia, in turn, directly exacerbates cognitive symptoms ("brain fog") and psychological distress, such as irritability and low mood.[44]

This creates a vicious cycle: depressed mood can then lower a woman's tolerance for VMS, making the *experience* of the symptoms feel more severe and disruptive.[27] This interconnectedness is clinically critical. It suggests that effectively treating the primary driver—for many women, the VMS—with a therapy like MHT or an NK3R antagonist may resolve or significantly mitigate the secondary and tertiary symptoms (insomnia, cognitive fog, mood changes) without requiring separate, additional interventions.

2.6 Chronic vs. Acute Symptomatology

A critical distinction for developing a long-term health strategy is the separation of menopausal symptoms into two categories: acute/transitional and chronic/progressive.

1. **Acute/Transitional Symptoms:** VMS, sleep disturbances, and mood changes are highly prevalent and disruptive *during the transition*.[26] While they can last for many years, VMS often (though not always) diminish in severity over time postmenopause.[27]
2. **Chronic/Progressive Conditions:** In stark contrast, Genitourinary Syndrome of Menopause (GSM) [1] and the musculoskeletal decline of sarcopenia and bone loss [2] are

chronic and *progressive*. They do *not* resolve without treatment and will worsen over time.[27]

This dichotomy demands a bifurcated management strategy. One strategy must address the "acute" symptoms impacting quality of life during the transition. The second must be a "chronic" strategy, instituting lifelong management for the progressive, postmenopausal conditions of GSM and musculoskeletal/bone health decline. A woman who chooses to "power through" her hot flashes and seeks no medical consultation may be entirely unaware that she is silently developing two other progressive conditions—GSM and osteoporosis—which can have severe, long-term consequences for her quality of life, sexual health, and skeletal integrity.

Part 3: Hormonal Management Strategies: The 2022 Medical Consensus

For symptomatic women, Menopausal Hormone Therapy (MHT) is the primary, most effective treatment. The medical consensus on its use is defined by the 2022 Hormone Therapy Position Statement from The Menopause Society (NAMS), a comprehensive update that clarifies the therapy's benefits and risks.[4] This position is echoed by other major international bodies, including the SOGC.[59]

3.1 A New Consensus: The Critical Reappraisal of the Women's Health Initiative (WHI)

For two decades, MHT has been a source of confusion, stemming from the initial 2002 report from the Women's Health Initiative (WHI).[4] That report, which linked MHT to increased risks of breast cancer and cardiovascular events, led to a dramatic and immediate global decline in MHT use.[60]

However, a subsequent decade of reappraisal has shown that the original WHI findings, while valid for the population studied, were *over-generalized* and misapplied to all menopausal women.[61] The fundamental flaw was one of demographics: the average WHI participant was 63 years old, and many were more than 10 or 20 years postmenopause, a population that already had a higher baseline risk of cardiovascular disease.[61]

This reappraisal led to the "Timing Hypothesis," now the central concept of modern MHT. Re-analysis of the WHI data [64] and subsequent studies confirmed that the risks and benefits of MHT are *critically dependent on the timing of initiation*.

This has culminated in the **NAMS 2022 Consensus**, which is the current standard of care:

- **Favorable Benefit-Risk Ratio:** For healthy, symptomatic women who are aged **younger than 60 years** OR who are **within 10 years of menopause onset**, the benefit-risk ratio of MHT is **favorable**.[5]
- **Less Favorable Benefit-Risk Ratio:** For women who *initiate* MHT *after* age 60 or *more than 10 years* from menopause onset, the benefit-risk ratio appears less favorable due to greater absolute risks of coronary heart disease (CHD), stroke, venous thromboembolism (VTE), and dementia.[5]

The primary indication for MHT remains the same: it is the **most effective treatment** for bothersome VMS and GSM, and it is also proven to prevent bone loss and fracture.[4]

3.2 MHT Formulations and Risk-Benefit Personalization

The NAMS 2022 statement emphasizes that "personalization is key".[4] Risks are not monolithic; they differ significantly based on therapy type, dose, route of administration, and the use of a progestogen.[5]

- **Systemic vs. Local Therapy:**
  - **Systemic MHT:** Delivered as pills, transdermal patches, or gels. The hormone is absorbed by the whole body. This is used to treat systemic symptoms like VMS and for osteoporosis prevention.[18]
  - **Local MHT:** Refers to low-dose vaginal estrogen (creams, tablets, rings). It is used *only* for the treatment of GSM symptoms in women who do not have other indications (like VMS) for systemic therapy.[5]
- **Estrogen-Only (ET) vs. Estrogen-Progestogen (EPT) Therapy:** This is the most critical safety distinction, based entirely on uterine status.
  - **Women with an intact uterus *must* take a progestogen in combination with estrogen (EPT)**.[18]
  - **Rationale:** Systemic estrogen taken alone (unopposed) stimulates the growth of the uterine lining (endometrium). This will cause endometrial hyperplasia and increases the incidence of endometrial cancer to about 30%.[18] The progestogen component is added solely for endometrial protection.[67]
  - **Women *without* a uterus (post-hysterectomy) should take Estrogen-Only Therapy (ET)**.[66] Adding a progestogen in this case adds unnecessary risk (as seen in

the WHI) with no benefit.

- **Route of Administration: Oral vs. Transdermal:**
  - **Oral Estrogen:** When taken as a pill, estrogen undergoes "first-pass metabolism" in the liver. This process impacts hepatic production of clotting factors, triglycerides, and C-reactive protein.[68]
  - **Transdermal Estrogen (Patches, Gels):** This route delivers estrogen directly into the bloodstream, avoiding the liver's first pass. Both the NAMS 2022 statement and the 2025 Korean Menopause Society guidelines highlight that transdermal routes may **decrease the risk of VTE and stroke** compared to oral routes.[20]
  - **Clinical Implication:** Transdermal MHT is generally the preferred route for women with risk factors such as hypertension, metabolic syndrome, or for those who smoke.[68]
- **Progestogen Type (A Key Nuance):**
  - A critical nuance for an advanced audience is that the small increased risk of breast cancer seen in the WHI EPT arm is associated with the *progestogen* component, not the estrogen.[68]
  - The WHI study used Medroxyprogesterone acetate (MPA), a synthetic progestin.[68]
  - Large observational cohort studies (like the E3N Cohort Study and a large-scale Finnish study) suggest that **micronized progesterone** (which is structurally identical to the body's own progesterone) or dydrogesterone may be associated with a **lower (or no) increased risk of breast cancer** compared to synthetic progestins like MPA.[68] This makes an EPT regimen of transdermal estradiol plus oral micronized progesterone a common choice for optimizing the risk-benefit profile.

3.3 MHT and Specific Disease Risks: A Nuanced Look

- **Breast Cancer:**
  - **ET (Estrogen-Only):** The WHI re-analysis provided a critical finding: CEE-only *did not* increase breast cancer risk. In fact, it showed a statistically significant *reduction* in breast cancer (HR 0.78) that persisted over a 20-year follow-up.[20]
  - **EPT (Estrogen + Progestin):** The WHI showed a *small* increased absolute risk with short-term use.[20] This risk is low (9 additional cases per 10,000 person-years in the WHI EPT arm) and becomes detectable after 3 to 5 years of continuous use.[5]
- **Venous Thromboembolism (VTE):** MHT *does* increase VTE (blood clot) risk, particularly *oral* MHT and during the first year of use.[68] This risk is highest in older women (>60).[5] As noted, transdermal routes largely mitigate this risk.[20]
- **Cardiovascular Disease (CVD):** This is the core of the "timing hypothesis."
  - **Initiated <60 years:** MHT does *not* elevate CHD risk and may be protective.[64] A WHI substudy of women aged 50-59 showed significantly *less* coronary artery

calcification (a marker of atherosclerotic plaque) in the CEE group compared to placebo.[69]
    - **Initiated >60 years:** Initiation in older women is associated with an *increased* risk of CHD and stroke.[5]
- **Contraindications:** MHT is absolutely contraindicated in women with [68]:
    - A history of estrogen-dependent malignancies (e.g., breast or endometrial cancer).
    - Active thromboembolic disease (VTE, pulmonary embolism) or a history of stroke or myocardial infarction.
    - Unexplained vaginal bleeding.
    - Active liver or gallbladder disease.

3.4 Testosterone Therapy: A Specific Indication

Testosterone therapy is often conflated with MHT, but it has a distinct and specific indication. The 2024 IMS White Paper and other global consensus statements confirm that the *only* evidence-based indication for testosterone therapy in postmenopausal women is for **Hypoactive Sexual Desire Disorder (HSDD)**—defined as distressing low libido.[72]

Evidence does *not* support its use as a primary treatment for cognitive symptoms, mood, bone health, or general well-being.[74] In most countries, it is prescribed "off-label" using a small fraction (e.g., 1/10th) of the dose from male-dosed gel preparations.[74]

3.5 Table 1: Comparative Analysis of Systemic MHT Formulations

This table summarizes the risk-benefit profile of MHT options based on key clinical guidelines.

Therapy Type / Regimen	**Route**	**Indication (Uterine Status)**	**Efficacy (VMS, Bone)**	**VTE / Stroke Risk**	**Breast Cancer Risk**	**Endometrial Cancer Risk**
Estrogen-Only (ET)	Oral or Transdermal	**No Uterus** (Post-Hy	High	Transdermal: Lower	**Reduced Risk** [20]	Not applicable

		stereco my)		risk Oral: Increase d risk 20		
EPT (Estroge n + Syntheti c Progesti n) *(e.g., CEE + MPA, the WHI regimen)*	Oral or Transder mal	**Intact Uterus**	High	Transder mal: Lower risk Oral: Increase d risk 20	**Small Increase d Risk** (after 3-5 years) [5]	**Protecte d** (Risk = Placebo) [18]
EPT (Estroge n + Micronize d Progeste rone)	Oral or Transder mal	**Intact Uterus**	High	Transder mal: Lower risk Oral: Increase d risk 20	**Lowest Risk** (Observa tional data suggests no significan t increase) [68]	**Protecte d** [18]

Part 4: Non-Hormonal Pharmacologic Management: The 2023 NAMS Position Statement

For women who have contraindications to MHT (e.g., breast cancer survivors) or who strongly prefer non-hormonal options, several evidence-based pharmacologic treatments are available.[34] These are detailed in **The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society**.[11]

4.1 Level I Evidence Therapies for VMS

NAMS 2023 assigns a **Level I (good and consistent scientific evidence)** recommendation to three classes of non-hormonal drugs for VMS.[76]

- **SSRIs/SNRIs:**
  - **Drugs:** This class includes Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs). The most-studied options include Paroxetine, Venlafaxine, Desvenlafaxine, Citalopram, and Escitalopram.[78]
  - **FDA Approval:** Paroxetine 7.5 mg (Brisdelle) is the *only* drug in this class that is FDA-approved *specifically for the treatment of VMS*.[81] Other uses are "off-label."
  - **Efficacy:** Systematic reviews show these medications can reduce VMS frequency and severity by 40-65%.[79] Their efficacy is consistently less than MHT but superior to placebo.[83]
- **Gabapentinoids:**
  - **Drug:** Gabapentin (a GABA analogue).[80]
  - **Efficacy:** Gabapentin has shown promising efficacy, reducing VMS by 45-60%.[80] It is also recommended by NAMS (Level I) for this indication.[76]

4.2 A Novel Mechanism: Neurokinin 3 Receptor (NK3R) Antagonists

The most significant recent development in non-hormonal management is the creation of a new class of drugs that directly targets the VMS pathophysiology.

- **Drug:** Fezolinetant (Brand name: Veozah).[6]
- **FDA Approval:** Approved in May 2023 for the treatment of moderate-to-severe VMS.[6]
- **Mechanism of Action:** This is a *first-in-class* non-hormonal therapy.[6] It is an NK3 receptor antagonist. It works by blocking the activity of neurokinin B on the KNDy neurons in the hypothalamus. This directly modulates the thermoregulatory center, interrupting the VMS cascade at its source.[29]
- **Clinical Trial Data:** The Phase 3 SKYLIGHT 1 & 2 trials, published in journals including *The Lancet* and *The Journal of Clinical Endocrinology & Metabolism*, demonstrated a rapid and statistically significant reduction in both the frequency and severity of VMS, with relief beginning as early as one week.[29]
- **Warnings and Contraindications:**
  - The FDA label includes a warning for potential **Hepatic Transaminase Elevation**

(liver enzyme elevation).[87]
    - **Required Monitoring:** Bloodwork to evaluate hepatic function (ALT/AST) is **required prior to initiation**, and at **3 months, 6 months, and 9 months** after starting therapy.[87]
    - **Contraindications:** Fezolinetant is contraindicated in women with known cirrhosis, severe renal impairment, or who are taking concomitant CYP1A2 inhibitors.[87]
    - **Adverse Reactions:** The most common side effects include abdominal pain, diarrhea, insomnia, and hepatic transaminase elevation.[87]

4.3 Non-Hormonal Management of GSM

The 2025 AUA/SUFU guidelines provide a clear framework for non-hormonal GSM management.[41]

- **First-Line (Over-the-Counter):** Vaginal moisturizers (used regularly) and vaginal lubricants (used for sexual activity) are recommended to improve symptoms of dryness and dyspareunia.[1] It is important to note that evidence *does not* support their use for improving or preventing *urinary* symptoms.[42]
- **Vaginal DHEA (Prasterone):** This is an intravaginal steroid (dehydroepiandrosterone) that is converted locally into estrogens and androgens. It is recommended by AUA/SUFU guidelines to improve vaginal dryness and dyspareunia.[41]
- **Oral Ospemifene:** This is an oral Selective Estrogen Receptor Modulator (SERM) that acts as an estrogen agonist in the vaginal tissue. It is recommended as an *oral* (non-vaginal) option for treating moderate-to-severe dyspareunia and vaginal dryness.[39]

4.4 Table 2: NAMS 2023-Endorsed Non-Hormonal Pharmacotherapies for VMS

This table compares the evidence-based non-hormonal options for VMS.

Medication Class	Drug(s)	Mechanism of Action	Efficacy (VMS Reduction)	Guideline Recommendation	Key Warnings / Monitoring

NK3R Antagonist	**Fezolinetant** (Veozah)	Targets KNDy neurons in the hypothalamic thermoregulatory center [32]	High (50-95%) [82]	NAMS 2023: Level I [76]	**Hepatic monitoring required** (Baseline, 3, 6, 9 mos). Contraindicated in liver/severe renal disease [87]
SSRI	**Paroxetine 7.5 mg** (Brisdelle)	Serotonin modulation [82]	Moderate (40-65%) [79]	NAMS 2023: Level I 76 FDA-approved for VMS 81	Standard SSRI warnings.
SNRI	**Venlafaxine**, Desvenlafaxine	Serotonin/Norepinephrine modulation [78]	Moderate (40-65%) [79]	NAMS 2023: Level I [76]	Standard SNRI warnings (e.g., blood pressure).
Gabapentinoid	**Gabapentin**	GABA analogue; modulates calcium channels [80]	Moderate (45-60%) [80]	NAMS 2023: Level I [76]	Drowsiness, dizziness.

Part 5: Non-Pharmacologic and Lifestyle-Based Medical Management

For an educated patient, lifestyle modifications should be presented not as generic wellness advice, but as specific, evidence-based medical interventions targeting distinct physiological processes.

5.1 Cognitive Behavioral Therapy (CBT): A First-Line Non-Pharmacologic Approach

CBT is a structured, evidence-based psychological therapy that has been proven effective for multiple menopausal symptoms.

- **CBT for VMS:**
  - **Evidence:** CBT is an effective treatment for VMS, recommended by NAMS.[89] The key clinical trials are MENOS 1 and MENOS 2.[80]
  - **Mechanism:** CBT works by significantly reducing VMS *severity* and their "problem rating" or *interference* with quality of life.[80] It does this by training the individual to change their cognitive and behavioral responses to a hot flash, breaking the cycle of catastrophic thoughts (e.g., "everyone is staring") and unhelpful behaviors (e.g., fleeing the room) that can amplify the distress.[92]
  - **Protocol:** The MENOS protocols are brief (4-6 sessions) and include psycho-education, stress reduction techniques, relaxation, paced breathing, and cognitive strategies to challenge unhelpful thoughts during a hot flash.[92]
  - **Delivery:** CBT has been proven effective in various accessible formats, including group therapy, self-help books, and online programs.[80]
- **CBT for Insomnia (CBT-I):**
  - **Evidence:** Sleep disturbances affect 40-60% of menopausal women.[14] CBT-I is a first-line, non-pharmacologic treatment for menopause-related insomnia.[94]
  - **Efficacy:** Clinical trials demonstrate that CBT-I is superior to simple sleep hygiene education and can lead to high rates of insomnia remission (70-84% in some studies).[93]
  - **Crossover Benefit:** Importantly, CBT-I not only improves sleep but also significantly reduces the *daytime interference* caused by hot flashes, even if it does not reduce their frequency.[93]

5.2 Exercise as Medicine: Countering Musculoskeletal Decline

While exercise is often recommended for VMS, the evidence for this indication is mixed or insufficient according to Cochrane reviews.[96] The *true* medical indication for exercise in menopause is to directly combat the progressive decline of the musculoskeletal system (sarcopenia and bone loss).

- **For Sarcopenia (Muscle Loss):** The accelerated loss of muscle mass (0.6% per year) and strength postmenopause is a primary driver of frailty.[50] **Resistance Training (RT)** is the primary medical intervention to counter this. Multiple meta-analyses confirm that prescriptive RT (e.g., 3 sessions per week, 60–90 minutes per session, for at least 12 weeks) effectively improves muscle mass and, most significantly, muscle strength (e.g., handgrip and knee extension) in postmenopausal women.[54]
- **For Bone Mineral Density (BMD):** To prevent osteoporosis, exercise must be "prescriptive." Systematic reviews show that **combined exercise interventions** (which include resistance training) are effective at *preserving* BMD at the critical sites of the lumbar spine, femoral neck, and total hip.[50] Protocols that are high-intensity (e.g., $\geq 70\%$ of 1-repetition-max) and performed 3 times per week appear to be optimal.[101]

5.3 Nutritional Science and Cardiometabolic Health

The menopausal transition is a period of *accelerated risk* for cardiovascular disease (CVD) and metabolic syndrome.[14] The American Heart Association (AHA) now identifies the menopause transition as a risk factor for CVD.[105] Nutritional science, therefore, becomes a targeted medical intervention.

- **For Cardiometabolic Health:** The AHA recommends dietary patterns like the **Mediterranean Diet** and **DASH** (Dietary Approaches to Stop Hypertension), which are plant-forward and high in fruits, vegetables, legumes, and lean protein (especially fish).[106] A 2024 review noted that to be maximally effective, these diets may need to be adapted for menopausal women to specifically address postprandial glycemic response and changes to the gut microbiome.[106]
- **For Musculoskeletal Symptoms (Arthralgia):** The MSM is linked to increased inflammation.[50] Dietary choices can modulate this. A pro-inflammatory diet (high in fat, low in omega-3s) is correlated with *higher* (worse) scores on the Menopause Rating Scale (MRS).[107] Conversely, anti-inflammatory dietary components, such as **Omega-3 fatty acids (EPA/DHA)**, may alleviate joint pain by inhibiting inflammatory pathways (e.g., NF-κB).[108] Phytoestrogens, such as soy isoflavones, have also been studied for menopausal joint pain and show potential for improving cartilage degeneration.[56]

Part 6: Management of Long-Term Health Risks: Osteoporosis

One of the most significant, "silent" consequences of long-term estrogen deficiency is osteoporosis, a progressive disease of decreased bone mass and microarchitectural deterioration that leads to fracture.[57] Management is a lifelong process, with clear guidelines from **The Menopause Society (2021 Position Statement)** [57] and **ACOG (2022 Clinical Practice Guideline)**.[112]

6.1 Screening and Diagnosis (ACOG & USPSTF)

The clinical pathway for bone health management begins with risk-stratified screening.

- **Who to Screen:**
  - All postmenopausal women **aged 65 and older** should be screened with bone density testing.[112]
  - Postmenopausal women **younger than 65** *if* they have one or more risk factors. Major risk factors include low body weight (thinness), history of previous fracture, smoking, excessive alcohol use, or a parental history of hip fracture.[57]
- **How to Screen:**
  - **DEXA Scan:** The preferred method is Dual-energy X-ray absorptiometry (DEXA) of the hip and lumbar spine.[113]
  - **Diagnosis:** Osteoporosis is diagnosed by *either* of the following [113]:
    1. A **T-score of −2.5 or less** at the femoral neck, total hip, or lumbar spine.[113]
    2. A **clinical fragility fracture** (a fracture occurring from a fall at less than standing height) *regardless of the T-score*.[113]
- **FRAX Assessment:** For women with *osteopenia* (a T-score between −1.0 and −2.5), the **FRAX (Fracture Risk Assessment Tool)** is used. This tool calculates the 10-year probability of a major fracture to determine if pharmacologic treatment is warranted.[111]

6.2 Non-Pharmacologic Management

These are universal recommendations for all postmenopausal women to maintain skeletal health [57]:

- **Nutrition:** Adequate intake of **Calcium** (RDA: 1,200 mg per day for women >50) and **Vitamin D** (RDA: 600-800 IU per day).[113]

- **Exercise:** Regular **weight-bearing exercise** and **resistance training**.[57]
- **Lifestyle:** Smoking cessation and moderation of alcohol intake (no more than 3 servings daily).[57]
- **Fall Prevention:** Strategies to reduce fall risk.[113]

6.3 Pharmacologic Treatment (ACOG 2022 / NAMS 2021)

Pharmacologic treatment is recommended for all patients at high risk of fracture (e.g., T-score $\leq$ −2.5 or a fragility fracture).[113]

- **MHT for Prevention:** MHT (estrogen) is FDA-approved for the *prevention* of postmenopausal osteoporosis and is highly effective at preserving BMD and reducing fractures.[50] For symptomatic women in the "window of opportunity," it serves the dual purpose of treating VMS and protecting bone.
- **First-Line Therapy (High Risk):**
  - **Bisphosphonates** (e.g., Alendronate, Risedronate) are the first-line *treatment* for most postmenopausal patients with osteoporosis.[109]
  - **Denosumab** (an anti-resorptive monoclonal antibody) is another first-line option.[116]
- **Second-Line Therapy (Very High Risk):**
  - For patients with *severe* osteoporosis (e.g., very low T-score or multiple vertebral fractures), **anabolic agents** that actively build bone are recommended.[116]
  - These include **Teriparatide** and **Abaloparatide** (PTH and PTH-related protein analogs), typically used for up to 2 years.[116]
  - **Romosozumab** (a monoclonal antibody that blocks sclerostin) increases bone formation and is used for 1 year. It carries a warning regarding potential increased risk of cardiovascular events.[116]
- **SERMs (Selective Estrogen Receptor Modulators):** Drugs like **Raloxifene** are an option for osteoporosis prevention and treatment, particularly for women who cannot take bisphosphonates.[109]

6.4 Table 3: Guideline-Based Management of Postmenopausal Osteoporosis

This table summarizes the clinical pathway for bone health management, from screening to tiered treatment.

Patient Category	Recommended Screening (ACOG/USPSTF)	Diagnostic Criteria (ACOG/NAMS)	First-Line Intervention	Second-Line Intervention (ACOG)	Guideline Source
All Postmenopausal Women	None (unless risk factors present)	N/A	**Lifestyle:** Calcium (1200 mg), Vit D (800 IU), Resistance Exercise [57]	N/A	NAMS 2021 [57]
Postmenopausal <65 with Risk Factors	DEXA Scan [115]	T-Score $\leq$ −2.5 or Fragility Fx [113]	Lifestyle [113]	N/A	ACOG 2022 [117]
All Women ≥ 65	DEXA Scan [112]	T-Score $\leq$ −2.5 or Fragility Fx [113]	Lifestyle [113]	N/A	ACOG 2022 [117]
Diagnosed Osteoporosis (High Risk)	Monitor w/ DEXA every 1-3 years [113]	T-Score $\leq$ −2.5 or Fragility Fx [113]	**Bisphosphonates** (First-Line) or Denosumab [113]	MHT (prevention), SERMs [109]	ACOG 2022 [113]
Severe Osteoporosis (Very High Risk)	Monitor w/ DEXA every 1-3 years [113]	T-Score $\leq$ −2.5 *and* fractures [119]	**Anabolic Agents** (Teriparatide, Abaloparatide, Romosozumab) [116]	Follow with antiresorptive (e.g., Bisphosphonate) [119]	ACOG 2022 [119]

Part 7: The Current Landscape: Navigating the 2024-2025 Medical Debate

The field of menopause management is currently in a dynamic period of high-level academic discourse. This debate centers on how to frame menopause—as a natural life stage or a medical condition—and how to balance evidence-based treatment with patient empowerment.

7.1 The *Lancet* 2024 Series: An Empowerment Model vs. "Overmedicalization"

In 2024, a series in *The Lancet* presented a powerful argument against what it termed the "overmedicalization" of menopause.[7] The authors argued that the current public narrative, heavily influenced by commercial interests, has become oversimplified, portraying menopause as a universal health problem that can *only* be solved by MHT.[7]

Key points of this critique include:

- This "overmedicalization" deflects attention from urgently needed societal shifts in how midlife women are viewed and supported in the workplace and society.[7]
- A new narrative should frame menopause as part of *healthy aging*, which would reduce stigma and empower women.[7]
- The authors argued that the evidence linking menopause to mental health issues for *all* women is *not* robust.[7]
- They called for an individualized, empowered approach that emphasizes accurate information and evidence-based non-medical options like lifestyle changes and CBT.[7]

7.2 The IMS 2024 White Paper: A Clinical Rebuttal and Clarification

In response to this discourse and widespread media confusion, the International Menopause Society (IMS) published its 2024 White Paper in the journal *Climacteric*, titled "Menopause

and MHT in 2024: addressing the key controversies".[9]

- **The Rebuttal:** The IMS and other society leaders (including past presidents of IMS and the Australasian Menopause Society) provided a direct response.[8] They agreed that empowerment has always been the goal of medical societies.[8] However, they argued that for the **over 25% of women with moderate-to-severe symptoms** that significantly impact quality of life, MHT is *not* an "overmedicalization" but rather an **essential, evidence-based, first-line medical treatment**.[8]
- **The "5Ws" of MHT:** To provide clarity, the IMS White Paper framed its recommendations around "The 5Ws of prescribing MHT" [9]:
  - **WHO** is MHT for? (Symptomatic women).
  - **WHAT** types and doses?
  - **WHEN** to start and stop? (Addressing the "timing hypothesis").
  - **WHY** is MHT important? (Quality of life, bone health).
  - **WHERE** can it be accessed?
- **The IMS Position:** The paper provides a "well-balanced educational narrative" that *reaffirms* the central, evidence-based role of MHT for symptom relief and skeletal benefits for appropriate candidates.[9]

7.3 The Future: Revisiting the "Window of Opportunity"

This evolving conversation is already pushing the boundaries of the 2022 consensus. Recent publications in 2024 and 2025 suggest the pendulum is swinging toward a more inclusive application of MHT.

- A 2025 review in *The Lancet Diabetes & Endocrinology* explicitly asks to **revisit the 10-year/age-60 initiation guidelines**.[122]
- The argument is that these strict limits are *denying* MHT to women who remain symptomatic outside this window, as well as denying its significant bone-protective effects to women who may need it.[122]
- Concurrently, 2024 publications in *JAMA* have highlighted MHT's association with *slower biological aging* [123] and confirmed its safety regarding coronary heart disease risk in younger postmenopausal women.[70]

7.4 Conclusion: A Synthesized, "Post-Debate" Model for the Educated Patient

The "best medical advice" in 2025 is not a binary choice between the "overmedicalization" cautioned by *The Lancet* and the MHT-centric model. The most sophisticated and effective approach is a *synthesis* of these perspectives, resulting in a tiered, evidence-based, and truly individualized model.

The Lancet 2024 series [7] correctly identifies the "empowerment framework" (societal support, lifestyle modification, CBT) that should serve as the *foundation of care* for *all* women navigating this transition. The IMS 2024 White Paper [9] correctly defends the "medical framework," which provides the *essential, first-line treatments* for the 25-80% of women who are symptomatic.

This whitepaper concludes that an optimal management strategy integrates both:

- **Tier 1 (Universal Foundation):** All women should adopt the empowerment model. This includes prescriptive lifestyle interventions (resistance training to combat sarcopenia [54], anti-inflammatory nutrition for cardiometabolic health [106]) and psychological tools (CBT for insomnia or VMS distress [89]).
- **Tier 2 (Symptom-Specific Intervention):**
  - For **mild VMS/insomnia**, or for women with **contraindications to MHT**, CBT and NAMS Level I non-hormonal therapies (SSRIs, Gabapentin, or Fezolinetant) are the evidence-based first line.[76]
  - For **moderate-to-severe VMS** in an appropriate candidate (within the "window of opportunity"), **MHT remains the most effective, first-line medical therapy**.[4]
  - For **GSM symptoms**, which are chronic and progressive, **local therapies** (low-dose vaginal estrogen, DHEA) are the standard of care to prevent long-term urogenital dysfunction.[41]

This integrated model respects the critique of a "one-size-fits-all" approach while simultaneously championing the robust, evidence-based medical therapies that remain the standard of care, allowing for a truly individualized and data-driven management plan.

Works cited

1. The Recent Review of the Genitourinary Syndrome of Menopause - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4561742/
2. The musculoskeletal syndrome of menopause: Climacteric - Taylor & Francis Online, accessed October 27, 2025, https://www.tandfonline.com/doi/abs/10.1080/13697137.2024.2380363
3. The musculoskeletal syndrome of menopause - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39077777/
4. 2022 Hormone Therapy Position Statement - The Menopause Society, accessed October 27, 2025,

https://menopause.org/wp-content/uploads/press-release/ht-position-statement-release.pdf
5. The 2022 hormone therapy position statement of The North American Menopause Society - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/35797481/
6. FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause, accessed October 27, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
7. The Lancet: Experts warn about the overmedicalisation of ..., accessed October 27, 2025, https://www.eurekalert.org/news-releases/1036090
8. Lancet series on Menopause 2024, accessed October 27, 2025, https://menopause.org.au/hp/gp-hp-resources/lancet-series-on-menopause-2024
9. Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39268862/
10. Position Statements | Professional Resources - The Menopause Society, accessed October 27, 2025, https://menopause.org/professional-resources/position-statements
11. Menopause Guidelines - Medscape Reference, accessed October 27, 2025, https://emedicine.medscape.com/article/264088-guidelines
12. Clinical Practice Guidelines | Endocrine Society, accessed October 27, 2025, https://www.endocrine.org/clinical-practice-guidelines
13. Position Papers and Consensus Statements - International Menopause Society, accessed October 27, 2025, https://www.imsociety.org/statements/position-papers-and-consensus-statements/
14. Menopause HUB - SOGC, accessed October 27, 2025, https://sogc.org/en/en/content/events/HUB-Pages/Menopause.aspx
15. Perimenopause - Symptoms and causes - Mayo Clinic, accessed October 27, 2025, https://www.mayoclinic.org/diseases-conditions/perimenopause/symptoms-causes/syc-20354666
16. Insights into Perimenopause: A Survey of Perceptions, Opinions on Treatment, and Potential Approaches - MDPI, accessed October 27, 2025, https://www.mdpi.com/2673-4184/5/1/4
17. accessed October 27, 2025, https://sogc.org/en/en/content/events/HUB-Pages/Menopause.aspx#:~:text=in%20specific%20situations.-,6,is%20the%20primary%20clinical%20marker.
18. Menopause - StatPearls - NCBI Bookshelf - NIH, accessed October 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507826/
19. Prevalence of Psychosomatic and Genitourinary Syndrome Among Menopausal Women: A Systematic Review and Meta-Analysis - ResearchGate, accessed October 27, 2025,

https://www.researchgate.net/publication/358986589_Prevalence_of_Psychosomatic_and_Genitourinary_Syndrome_Among_Menopausal_Women_A_Systematic_Review_and_Meta-Analysis
20. The 2022 Hormone Therapy Position Statement of the North American Menopause Society, accessed October 27, 2025, https://menopause.org.au/hp/position-statements/the-2022-hormone-therapy-position-statement-of-the-north-american-menopause-society
21. NAMS 2022 Hormone Therapy Position Statement - Let's Talk Menopause, accessed October 27, 2025, https://www.letstalkmenopause.org/our-articles/nams-2022-hormone-therapy-position-statement
22. Perimenopause: symptoms and management - The Pharmaceutical Journal, accessed October 27, 2025, https://pharmaceutical-journal.com/article/ld/perimenopause-symptoms-and-management
23. Treatment of the Symptoms of Menopause Guideline Resources - Endocrine Society, accessed October 27, 2025, https://www.endocrine.org/clinical-practice-guidelines/treatment-of-menopause
24. The 2020 Menopausal Hormone Therapy Guidelines - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7475284/
25. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline - Oxford Academic, accessed October 27, 2025, https://academic.oup.com/jcem/article/100/11/3975/2836060
26. ACOG Practice Bulletin No. 141: management of menopausal symptoms - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/24463691/
27. Perimenopause: From Research to Practice - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4834516/
28. Vasomotor Symptoms and Menopause: Findings from the Study of Women's Health Across the Nation - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3185243/
29. Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10769482/
30. Treatment of Vasomotor Symptoms - Journal of the American Board of Family Medicine, accessed October 27, 2025, https://www.jabfm.org/content/37/5/923.full.pdf
31. THIS IS YOUR BRAIN ON MENOPAUSE - SOGC, accessed October 27, 2025, https://sogc.org/common/Uploaded%20files/ACSC/ACSC2024/KNDy%20Neurons%20Edmonton%20SOGC%202024%20copy%20(1).pdf
32. Fezolinetant (VEOZAH) National Drug Monograph August 2023 - VA.gov, accessed October 27, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Fezolinetant_VEOZAH_Monograph_Aug_2023.pdf
33. Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine - saegre, accessed October

27, 2025, http://www.saegre.org.ar/biblioteca/climaterio/Guideline%20No.%20422a_%20Canada.pdf
34. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10870088/
35. Genitourinary syndrome of menopause - RACGP, accessed October 27, 2025, https://www.racgp.org.au/afp/2017/july/genitourinary-syndrome-of-menopause
36. Genitourinary Syndrome of Menopause - StatPearls - NCBI Bookshelf - NIH, accessed October 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559297/
37. Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 20 - Oxford Academic, accessed October 27, 2025, https://academic.oup.com/smr/advance-article-pdf/doi/10.1093/sxmrev/qeaf055/64345201/qeaf055.pdf
38. Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024) - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/40981832/
39. Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024) | Request PDF - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/395720679_Genitourinary_syndrome_of_menopause_GSM_recommendations_from_the_Fifth_International_Consultation_on_Sexual_Medicine_ICSM_2024
40. Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024) - Oxford Academic, accessed October 27, 2025, https://academic.oup.com/smr/advance-article/doi/10.1093/sxmrev/qeaf055/8261468?searchresult=1
41. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, accessed October 27, 2025, https://www.auajournals.org/doi/10.1097/JU.0000000000004589
42. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025), accessed October 27, 2025, https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause
43. Executive Summary: The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/41026118/
44. Depression and emotional aspects of the menopause | British Columbia Medical Journal, accessed October 27, 2025, https://bcmj.org/articles/depression-and-emotional-aspects-menopause
45. Mood and Menopause: Findings from the Study of Women's Health Across the Nation (SWAN) over ten years - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3197240/

46. Etiology, symptoms and treatment of peri-menopausal depression, accessed October 27, 2025, https://www.jpccr.eu/pdf-162920-89343?filename=Etiology_%20symptoms%20and.pdf
47. Severe mental illness and the perimenopause - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11669460/
48. Oestrogen and cognition in the perimenopause and menopause, accessed October 27, 2025, https://menopause.org.au/hp/information-sheets/oestrogen-and-cognition-in-the-perimenopause-and-menopause
49. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6843314/
50. The Musculoskeletal Syndrome of Menopause By Dr. Michele Couri, MD, FACOG, ABIHM, accessed October 27, 2025, https://www.couricenter.com/articles/the-musculoskeletal-syndrome-of-menopause-by-dr-michele-couri-md-facog-abihm/
51. Musculoskeletal Syndrome of Menopause: What You Need to Know - The 'Pause Life, accessed October 27, 2025, https://thepauselife.com/blogs/the-pause-blog/musculoskeletal-syndrome-of-menopause-what-you-need-to-know
52. The musculoskeletal syndrome of menopause - Taylor & Francis Online, accessed October 27, 2025, https://www.tandfonline.com/doi/full/10.1080/13697137.2024.2380363
53. Musculoskeletal Disorders and Menopause - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6430266/
54. The effects of exercise training on body composition in postmenopausal women: a systematic review and meta-analysis - Frontiers, accessed October 27, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1183765/full
55. The Effect of Menopause on the Musculoskeletal System (Chapter 13), accessed October 27, 2025, https://www.cambridge.org/core/books/managing-the-menopause/effect-of-menopause-on-the-musculoskeletal-system/72211398640433922575A72E8C25D138
56. Menopause Joint Pain, accessed October 27, 2025, https://onlinemenopausecentre.com/menopause-joint-pain/
57. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/34448749/
58. Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper | Request PDF - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/384018974_Menopause_and_MHT_in_2024_addressing_the_key_controversies_-_an_International_Menopause_Society_White_Paper

59. A pragmatic approach to the management of menopause - CMAJ, accessed October 27, 2025, https://www.cmaj.ca/content/195/19/E677
60. Full article: Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper - Taylor & Francis Online, accessed October 27, 2025, https://www.tandfonline.com/doi/full/10.1080/13697137.2024.2394950
61. The Women's Health Initiative Study and Hormone Therapy -- what have we learned 10 years on?, accessed October 27, 2025, https://womensbrainhealth.org/think-tank/come-to-think-of-it/the-womens-health-initiative-study-and-hormone-therapy-what-have-we-learned-10-years-on
62. Menopausal hormone therapy and breast cancer risk: 21 years from the WHI clinical studies - Gynecological and Reproductive Endocrinology & Metabolism, accessed October 27, 2025, https://gremjournal.com/wp-content/uploads/2024/11/86-89.pdf
63. Commentary Hormones and Heart Disease in Women: The Timing Hypothesis, accessed October 27, 2025, https://academic.oup.com/aje/article-pdf/166/5/506/200778/kwm214.pdf
64. What the Women's Health Initiative has taught us about menopausal hormone therapy - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6490107/
65. (PDF) The timing hypothesis for coronary heart disease prevention with hormone therapy: Past, present and future in perspective - ResearchGate, accessed October 27, 2025, https://www.researchgate.net/publication/225051876_The_timing_hypothesis_for_coronary_heart_disease_prevention_with_hormone_therapy_Past_present_and_future_in_perspective
66. Menopause hormone therapy: Is it right for you? - Mayo Clinic, accessed October 27, 2025, https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372
67. Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutr - SOGC, accessed October 27, 2025, https://sogc.org/common/Uploaded%20files/ACSC/ACSC2025/gui422aCPG2110E.pdf
68. The 2025 Menopausal Hormone Therapy Guidelines - Korean ..., accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12438153/
69. A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50–59 Years of Age - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4313058/
70. JAMA: Hormone therapy might remain a safe 'first line' treatment for postmenopausal women - Formidable, accessed October 27, 2025, https://beformidable.com/p/jama-hormone-therapy-might-remain-a-safe-first-line-treatment-for-postmenopausal-women
71. Menopausal Hormone Replacement Therapy and Reduction of All-Cause

Mortality and Cardiovascular Disease: It's About Time and Timing - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/
72. Full article: State of the art in menopause: current best practice approaches from the IMS World Congress 2024, Melbourne - Taylor & Francis Online, accessed October 27, 2025, https://www.tandfonline.com/doi/full/10.1080/13697137.2025.2457993
73. State of the art in menopause: current best practice approaches from the IMS World Congress 2024, Melbourne - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39928407/
74. Appendix 1. Key Points Summary of the Principles of Prescribing Menopause Hormone Therapy (MHT) – the 5Ws, accessed October 27, 2025, https://journals.co.za/doi/pdf/10.10520/ejc-mp_sagp_v5_n3_a8
75. Androgens for genitourinary and vasomotor symptoms associated with menopause - Lara, LA - 2025 | Cochrane Library, accessed October 27, 2025, https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016052/abstract
76. The 2023 nonhormone therapy position statement of The North ..., accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/37252752/
77. The Menopause Society: Hormone Therapy Statement - The ObG Project, accessed October 27, 2025, https://www.obgproject.com/2022/11/21/north-american-menopause-society-releases-2017-hormone-therapy-statement/
78. NonHormonal Treatments for Menopausal Symptoms, accessed October 27, 2025, https://menopause.org.au/hp/information-sheets/nonhormonal-treatments-for-menopausal-symptoms
79. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/24944075/
80. Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9938702/
81. New Guidance from ACOG for Treatment of Women with Menopausal Symptoms, accessed October 27, 2025, https://www.jwatch.org/na33279/2014/01/13/new-guidance-acog-treatment-women-with-menopausal-symptoms
82. FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12401328/
83. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/16670414/
84. Fezolinetant: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 27, 2025, https://go.drugbank.com/drugs/DB15669
85. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT - PubMed, accessed October 27,

2025, https://pubmed.ncbi.nlm.nih.gov/36734148/
86. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/36924778/
87. This label may not be the latest approved by FDA. For current ..., accessed October 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf
88. New AUA Guideline on GSM Highlights Urology's Role in Menopause Care, accessed October 27, 2025, https://www.med.unc.edu/urology/new-aua-guideline-on-gsm-highlights-urologys-role-in-menopause-care/
89. Cognitive behavioral therapy for menopausal symptoms - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/32627593/
90. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6445536/
91. The effects of psychological interventions on menopausal hot flashes: A systematic review, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9260068/
92. (PDF) Cognitive behavioral interventions for the treatment of ..., accessed October 27, 2025, https://www.researchgate.net/publication/262794700_Cognitive_behavioral_interventions_for_the_treatment_of_menopausal_symptoms
93. Telephone Delivered Cognitive-Behavior Therapy for Insomnia in Midlife Women with Vasomotor Symptoms: An MsFLASH Randomized Trial - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4935624/
94. Treating chronic insomnia in postmenopausal women: a randomized clinical trial comparing cognitive-behavioral therapy for insomnia, sleep restriction therapy, and sleep hygiene education - Oxford Academic, accessed October 27, 2025, https://academic.oup.com/sleep/article/42/2/zsy217/5179856
95. COGNITIVE BEHAVIORAL THERAPY FOR SLEEP - My Menoplan, accessed October 27, 2025, https://mymenoplan.org/cognitive-behavioral-therapy-for-sleep/
96. Exercise for vasomotor menopausal symptoms - Daley, A - 2007 | Cochrane Library, accessed October 27, 2025, https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006108.pub2/abstract
97. Exercise for vasomotor menopausal symptoms - Cochrane, accessed October 27, 2025, https://www.cochrane.org/evidence/CD006108_exercise-vasomotor-menopausal-symptoms
98. The Effect of Resistance Training on the Rehabilitation of Elderly Patients with Sarcopenia: A Meta-Analysis - ResearchGate, accessed October 27, 2025,

https://www.researchgate.net/publication/365658717_The_Effect_of_Resistance_Training_on_the_Rehabilitation_of_Elderly_Patients_with_Sarcopenia_A_Meta-Analysis
99. Effect of non-pharmacological interventions on the prevention of sarcopenia in menopausal women: a systematic review and meta-analysis of randomized controlled trials - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10647115/
100. Comparative efficacy different resistance training protocols on bone mineral density in postmenopausal women: A systematic review and network meta-analysis - Frontiers, accessed October 27, 2025, https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2023.1105303/full
101. Optimal resistance training parameters for improving bone mineral density in postmenopausal women: a systematic review and meta-analysis - PMC - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12107943/
102. Exercise training and bone mineral density in postmenopausal women: an updated systematic review and meta-analysis of intervention studies with emphasis on potential moderators - NIH, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10282053/
103. The Effectiveness of Combined Exercise Interventions for Preventing Postmenopausal Bone Loss: A Systematic Review and Meta-analysis | Journal of Orthopaedic & Sports Physical Therapy - jospt, accessed October 27, 2025, https://www.jospt.org/doi/10.2519/jospt.2017.6969
104. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association, accessed October 27, 2025, https://www.ahajournals.org/doi/10.1161/CIR.0000000000000912
105. Clinical impact of 2020 American Heart Association statement on menopause and cardiovascular disease risk, accessed October 27, 2025, https://www.ccjm.org/content/89/1/13
106. Precision Nutrition for Management of Cardiovascular Disease Risk During Menopause - PMC - PubMed Central, accessed October 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11394930/
107. Full article: Dietary Inflammatory Index: is it really associated with postmenopausal symptoms? - Taylor & Francis Online, accessed October 27, 2025, https://www.tandfonline.com/doi/full/10.1080/13697137.2025.2524174?src=
108. Association Between Protein-Rich Foods, Nutritional Supplements, and Age of Natural Menopause and Its Symptoms - MDPI, accessed October 27, 2025, https://www.mdpi.com/2072-6643/17/2/356
109. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/11875327/
110. Osteoporosis in Females - StatPearls - NCBI Bookshelf, accessed October 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559156/
111. Management of osteoporosis in postmenopausal women: the 2021 position

statement of The North American Menopause Society - Huntington Hospital, accessed October 27, 2025, https://www.huntingtonhealth.org/wp-content/uploads/2024/09/2021-osteoporosis-position-statement.pdf
112. Osteoporosis Prevention, Screening, and Diagnosis: ACOG Recommendations | AAFP, accessed October 27, 2025, https://www.aafp.org/pubs/afp/issues/2022/1100/practice-guidelines-osteoporosis.html
113. Professional Recommendations: Management of Postmenopausal Osteoporosis, accessed October 27, 2025, https://www.obgproject.com/2022/07/17/acog-recommendations-management-of-postmenopausal-osteoporosis/
114. ACOG Releases Guidelines for Clinical Management of Osteoporosis - AAFP, accessed October 27, 2025, https://www.aafp.org/pubs/afp/issues/2004/0315/p1558.html
115. Recommendation: Osteoporosis to Prevent Fractures: Screening - uspstf, accessed October 27, 2025, https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
116. Osteoporosis: Common Questions and Answers - AAFP, accessed October 27, 2025, https://www.aafp.org/pubs/afp/issues/2023/0300/osteoporosis.html
117. USPSTF Recommendations: Screening for Osteoporosis to Prevent Fractures - The ObG Project, accessed October 27, 2025, https://www.obgproject.com/tag/bone-density/
118. Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/35594133/
119. Osteoporosis Treatment for Postmenopausal Women at High Risk for Fracture - The ObG Project, accessed October 27, 2025, https://www.obgproject.com/tag/osteoporosis/
120. Menopausal Hormone Therapy: Limited Benefits, Significant Harms - AAFP, accessed October 27, 2025, https://www.aafp.org/pubs/afp/issues/2025/0700/editorials-menopausal-hormone-therapy.html
121. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper - Semantic Scholar, accessed October 27, 2025, https://www.semanticscholar.org/paper/Menopause-and-MHT-in-2024%3A-addressing-the-key-%E2%80%93-an-Panay-Ang/5d8c613aee8802c0f8e709e78d6b39e6aa3aa672
122. Is it time to revisit the recommendations for initiation of menopausal ..., accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39419045/
123. Hormone Therapy Associated With Slower Biological Aging in Menopause - PubMed, accessed October 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39302684/